Original Source

With Novo Nordisk's semaglutide patent expiring in China, over 10 Chinese drugmakers are vying for regulatory approval for their weight-loss drugs, intensifying competition in a market projected to reach $14 billion by 2030.

China's Weight-Loss Drug Market Heats Up

Novo Nordisk's blockbuster weight-loss drug, semaglutide, lost its patent protection in China on March 20, paving the way for domestic rivals. At least 10 weight-loss injections and oral pills are currently awaiting regulatory approval in China. This influx comes as the market is projected to reach approximately US$14 billion by 2030, setting the stage for increased competition with global pharmaceutical giants.

Accelerated Approvals and Out-licensing Deals

China's drug regulator is accelerating approvals for innovative therapies, a move that benefits local drugmakers. This trend is further supported by a surge in out-licensing deals with global pharmaceutical companies. Last year, semaglutide alone generated about US$35 billion in global revenue, highlighting the lucrative potential of the weight-loss drug sector.

*Source: SCMP China (2026-03-26)*

Related Articles